ARTBIO is at the forefront of cancer treatment innovation, focusing on the development of a new class of alpha radioligand therapies (ARTs). These therapies utilize alpha particles, specifically the isotope lead-212 (Pb-212), which is recognized for its potential to deliver superior efficacy and safety compared to traditional beta radioligand therapies. The company’s approach is holistic, integrating a deep understanding of cancer biology with a robust infrastructure for the design, manufacturing, and distribution of its therapies. ARTBIO's pipeline includes several promising programs, with its lead candidate, AB001, currently in first-in-human trials, and additional undisclosed targets in various stages of development.

The company employs its proprietary AlphaDirect™ technology, which facilitates the efficient isolation of Pb-212, enabling a distributed manufacturing model that enhances the reliability of ART production and delivery. This innovative approach allows ARTBIO to target specific tumor types effectively while minimizing damage to healthy tissues. By collaborating with partners like 3B Pharmaceuticals, ARTBIO aims to expand its pipeline and address a broader range of solid tumors, thereby redefining treatment paradigms in oncology and improving patient outcomes through targeted therapies.

United States

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

ARTBIO

Company Details